Dr Reddy's Labs
Drug Manufacturers - Specialty & Generic · DRREDDY
Mega CapHealthcareMature Stable
G V Prasad
Co-Chairman and Managing Director · Pragmatic
Company DNA
Innovation-Led
About
Dr Reddy's Labs is a Mega Cap company in the Healthcare sector, listed on NSE as DRREDDY. With a market cap of ₹107K Cr and revenue of ₹33K Cr, it is currently in the Mature Stable phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Strong focus on global R&D and pharmaceutical innovation with a legacy of complex generic development. Its strategic mandate: To maintain market leadership amidst generic commoditization, the firm requires a pivot toward high-margin biosimilars and proprietary drug R&D.
FAQ
What kind of company is Dr Reddy's Labs?
Dr Reddy's Labs is a Mega Cap Healthcare company (DRREDDY) in the Mature Stable phase with a market cap of ₹107K Cr. It is classified as Innovation-Led in culture.
What is Dr Reddy's Labs's culture and work environment like?
Dr Reddy's Labs has a Innovation-Led culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Strong focus on global R&D and pharmaceutical innovation with a legacy of complex generic development.
Who leads Dr Reddy's Labs?
Dr Reddy's Labs is led by G V Prasad (Co-Chairman and Managing Director), a Pragmatic leader with 35 years of experience.
What are Dr Reddy's Labs's financials?
Dr Reddy's Labs reported revenue of ₹33K Cr in FY25 with a 5-year revenue CAGR of 14.9%. Operating margin: 22.1%. Market cap: ₹107K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleMature Stable
Strong focus on global R&D and pharmaceutical innovation with a legacy of complex generic development.
Mandate
To maintain market leadership amidst generic commoditization, the firm requires a pivot toward high-margin biosimilars and proprietary drug R&D.
To maintain market leadership amidst generic commoditization, the firm requires a pivot toward high-margin biosimilars and proprietary drug R&D.
Financials
Revenue FY25₹33K Cr
PAT FY25₹6K Cr
Rev CAGR 5Y14.9%
OPM22.1%
NPM17.4%
ROE17%
ROCE19.9%
P/E19
Fwd P/E23.5
P/B2.9
D/E18
Mkt Cap₹107K Cr
Promoter29.5%
Institutional52.7%
Similar Culture
Could You Lead Dr Reddy's Labs?
Take the Genome Benchmark →